FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Hikma Pharmaceuticals USA Inc.)

View source ↗

Summary

FDA issued a supplemental approval for mycophenolate mofetil (Hikma) to update the drug's labeling under an existing approval.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Transplant Rejection
• Kidney Transplant Rejection
• Liver Transplant Rejection
• Lupus Nephritis
• Systemic Lupus Erythematosus

Drugs mentioned

• MYCOPHENOLATE MOFETIL (MYCOPHENOLATE MOFETIL)

Snippet

SUPPL AP for MYCOPHENOLATE MOFETIL (MYCOPHENOLATE MOFETIL)